PMID- 18803764
OWN - NLM
STAT- MEDLINE
DCOM- 20090402
LR  - 20220409
IS  - 1365-2249 (Electronic)
IS  - 0009-9104 (Print)
IS  - 0009-9104 (Linking)
VI  - 153
IP  - 3
DP  - 2008 Sep
TI  - Immunoglobulin E antibodies from pancreatic cancer patients mediate 
      antibody-dependent cell-mediated cytotoxicity against pancreatic cancer cells.
PG  - 401-9
LID - 10.1111/j.1365-2249.2008.03726.x [doi]
AB  - In addition to allergy and parasitic infections, immunoglobulin E (IgE) has been 
      shown recently to possess anti-viral and anti-cancer effects. We investigated 
      serum levels of IgE, its low-affinity receptor, soluble CD23 (sCD23) in patients 
      with pancreatic cancer and the effect of IgE against pancreatic cancer cells. 
      Twelve patients were evaluated for pancreatic cancer by imaging and confirmed by 
      biopsy. Fifteen healthy volunteers served as controls. Serum Igs (IgG, IgM, IgA, 
      IgE) and sCD23 levels were determined (enzyme-linked immunosorbent assay, 
      nephelometry) and the presence of cancer-specific IgE was assessed (fluorescence 
      microscopy, Western blot). IgE anti-cancer activity was determined by 
      antibody-dependent cell-mediated cytotoxicity (ADCC). Serum levels of IgE and 
      sCD23 were elevated significantly in patients with pancreatic cancer versus 
      controls, whereas no differences were observed in other Ig isotypes (IgG, IgM, 
      IgA). Flow cytometry and immunofluorescence microscopy demonstrated similar 
      presence of IgG and IgE pancreatic cancer Igs. However, Western blot analysis 
      indicated differences in IgG and IgE antigen-specific antibodies; IgE antibody 
      recognized a 50 kD protein. ADCC studies demonstrated that serum and purified 
      IgE-mediated cytotoxicity against pancreatic cancer cells, effects which were 
      reversed with anti-IgE neutralizing antibody and IgE depletion (immunoaffinity); 
      greater cytotoxicity was observed in patient serum when compared with healthy 
      controls. These data suggest that IgE and sCD23 may serve as useful biomarkers 
      for patients with pancreatic cancer and may be important in the immune response 
      to this disease in that IgE-directed therapy may help to direct treatment.
FAU - Fu, S L
AU  - Fu SL
AD  - Department of Surgery, SUNY Downstate Medical Center, Brooklyn, NY, USA.
FAU - Pierre, J
AU  - Pierre J
FAU - Smith-Norowitz, T A
AU  - Smith-Norowitz TA
FAU - Hagler, M
AU  - Hagler M
FAU - Bowne, W
AU  - Bowne W
FAU - Pincus, M R
AU  - Pincus MR
FAU - Mueller, C M
AU  - Mueller CM
FAU - Zenilman, M E
AU  - Zenilman ME
FAU - Bluth, M H
AU  - Bluth MH
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PL  - England
TA  - Clin Exp Immunol
JT  - Clinical and experimental immunology
JID - 0057202
RN  - 0 (Immunoglobulin A)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Immunoglobulin M)
RN  - 0 (Receptors, IgE)
RN  - 37341-29-0 (Immunoglobulin E)
SB  - IM
MH  - Adenocarcinoma/*blood/immunology
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antibody-Dependent Cell Cytotoxicity/*immunology
MH  - Blotting, Western
MH  - Case-Control Studies
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Female
MH  - Humans
MH  - Immunoglobulin A/blood
MH  - Immunoglobulin E/*blood
MH  - Immunoglobulin G/blood
MH  - Immunoglobulin M/blood
MH  - Male
MH  - Microscopy, Fluorescence
MH  - Middle Aged
MH  - Nephelometry and Turbidimetry
MH  - Pancreatic Neoplasms/*blood/immunology
MH  - Receptors, IgE/*blood/immunology
PMC - PMC2527370
EDAT- 2008/09/23 09:00
MHDA- 2009/04/03 09:00
PMCR- 2009/09/01
CRDT- 2008/09/23 09:00
PHST- 2008/09/23 09:00 [pubmed]
PHST- 2009/04/03 09:00 [medline]
PHST- 2008/09/23 09:00 [entrez]
PHST- 2009/09/01 00:00 [pmc-release]
AID - CEI3726 [pii]
AID - 10.1111/j.1365-2249.2008.03726.x [doi]
PST - ppublish
SO  - Clin Exp Immunol. 2008 Sep;153(3):401-9. doi: 10.1111/j.1365-2249.2008.03726.x.